Discover
AXSM
Axsome Therapeutics, Inc.
221.72
2 x 221.44
2 x 221.90
bid
ask
+
0.83
0.38%
01:41 PM
timesize
| Ytd | 21.40% | |
| 1y | 113.27% |
217.86
day range
222.99
103.40
52 week range
260.19
| Open | 221.09 | Prev Close | 220.89 | Low | 217.86 | High | 222.99 | Mkt Cap | 11.41B |
| Vol | 377.96K | Avg Vol | 862.09K | EPS | -3.83 | P/E | -57.89 | Forward P/E | 36.69 |
| Beta | 0.65 | Short Ratio | 2.52 | Inst. Own | 73.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 236.16 | 200-d Avg | 187.77 | 1yr Est | 282.32 |
| Income Statement | |||
| Total Revenue | 191.20M | ||
| Revenues (USD) | 191.20M | ||
| Cost of Revenue | 14.73M | ||
| Gross Profit | 176.48M | ||
| Operating Expenses | 239.84M | ||
| Research and Development Expense | 52.68M | ||
| Selling, General and Administrative Expense | 185.00M | ||
| Operating Income | -63.36M | ||
| Interest Expense | 1.19M | ||
| Net Income | -64.54M | ||
| Net Income Common Stock | -64.54M | ||
| Net Income Common Stock (USD) | -64.54M | ||
| Consolidated Income | -64.54M | ||
| Earnings per Basic Share | -1.26 | ||
| Earnings per Basic Share (USD) | -1.26 | ||
| Earnings per Diluted Share | -1.26 | ||
| Earning Before Interest & Taxes (EBIT) | -63.36M | ||
| Earning Before Interest & Taxes (USD) | -63.36M | ||
| Weighted Average Shares | 51.20M | ||
| Weighted Average Shares Diluted | 51.20M | ||
| Balance Sheet | |||
| Cash and Equivalents | 305.11M | ||
| Cash and Equivalents (USD) | 305.11M | ||
| Trade and Non-Trade Receivables | 251.06M | ||
| Current Assets | 611.21M | ||
| Property, Plant & Equipment Net | 20.58M | ||
| Total Assets | 713.61M | ||
| Debt Current | 70.63M | ||
| Total Debt | 216.71M | ||
| Current Liabilities | 439.21M | ||
| Debt Non-Current | 146.08M | ||
| Total Liabilities | 659.02M | ||
| Accumulated Retained Earnings (Deficit) | -1.37B | ||
| Shareholders Equity | 54.59M | ||
| Shareholders Equity (USD) | 54.59M | ||
| Assets Non-Current | 102.40M | ||
| Total Debt (USD) | 216.71M | ||
| Goodwill and Intangible Assets | 50.99M | ||
| Inventory | 31.52M | ||
| Liabilities Non-Current | 219.81M | ||
| Trade and Non-Trade Payables | 106.70M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 3.21M | ||
| Net Cash Flow from Financing | 2.99M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -17.83M | ||
| Capital Expenditure | -121.00K | ||
| Issuance (Purchase) of Equity Shares | 16.32M | ||
| Issuance (Repayment) of Debt Securities | -672.00K | ||
| Net Cash Flow from Investing | -121.00K | ||
| Net Cash Flow from Operations | -20.70M | ||
| Share Based Compensation | 23.44M | ||